Frontlight ResearchEarly access
Not yet taking people in United StatesPhase 1
People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness
Key facts
- Who runs it
- National Institute of Allergy and Infectious Diseases (NIAID)
- Where
- Aurora, Baltimore, Birmingham, Boston, Chapel Hill, Chicago, Cincinnati, Cleveland, Columbus, Greensboro, Houston, Los Angeles, Nashville, New York, Newark, Pittsburgh, San Diego, San Francisco, Seattle, Torrance, and Washington D.C., United StatesSee the 24 sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 38 people, planned
- Starts
- 1 Feb 2028
- Expected to end
- 26 Oct 2030
- Type of study
- Interventional
- Treatments tested
- Lenacapavir
- Cabotegravir
- Bictegravir/Emtricitabine/Tenofovir Alafenamide
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Documented HIV-1 infection
- Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
- HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
- Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
- At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
- Adequate laboratory parameters within 60 days prior to study entry:; Absolute neutrophil count >600/mm3; Hemoglobin ≥7.0 g/dL; Platelet count >50,000/μL; AST and ALT ≤3 × upper limit of normal; Estimated glomerular filtration rate >15 mL/min/1.73 m²
- For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
- Ability and willingness to provide informed consent
- Connected to a medical clinic with access to HIV care and antiretroviral therapy
Who cannot take part
- Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
- Prior use of lenacapavir
- Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
- Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
- Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
- No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
- Serious medical or psychiatric condition
- Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
- Child-Pugh Class C cirrhosis
- Current pregnancy or breastfeeding
Where in United States
- University of Colorado Hospital (Site ID: 6101)Aurora, United StatesContact: Nicola HaakonsenNot yet recruiting
- Johns Hopkins University (Site ID: 201)Baltimore, United StatesContact: Rebecca L BeckerNot yet recruiting
- Alabama (Site ID: 31788)Birmingham, United StatesContact: Heather LoganNot yet recruiting
- Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)Boston, United StatesContact: Hannah JordanNot yet recruiting
- Massachusetts General Hospital (Site ID: 101)Boston, United StatesContact: Amy SbrollaNot yet recruiting
- Chapel Hill (Site ID: 3201)Chapel Hill, United StatesContact: Erin Elizabeth HoffmanNot yet recruiting
- Northwestern University (Site ID: 2701)Chicago, United StatesContact: Sherryl L WolfeNot yet recruiting
- Cincinnati Clinical Research Site (Site ID: 2401)Cincinnati, United StatesContact: Michelle SaemannNot yet recruiting
- Case Clinical Research Site (Site ID: 2501)Cleveland, United StatesContact: Julie PasternakNot yet recruiting
- Ohio State University (Site ID: 2301)Columbus, United StatesContact: Lindsay SummersNot yet recruiting
- Greensboro (Site ID: 3203)Greensboro, United StatesContact: Kelly PhillipsNot yet recruiting
- Houston Advancing Research Team (Site ID: 31473)Houston, United StatesContact: Maria Laura MartinezNot yet recruiting
- University of California, Los Angeles CARE Center (Site ID: 601)Los Angeles, United StatesContact: Aleen KhodabakhshianNot yet recruiting
- Vanderbilt Therapeutics (VT) (Site ID: 3652)Nashville, United StatesContact: Beverly WoodwardNot yet recruiting
- Columbia Physicians & Surgeons (P&S) (Site ID: 30329)New York, United StatesContact: Brett T GrayNot yet recruiting
- Weill Cornell Chelsea (Site ID: 7804)New York, United StatesContact: Mauricio VergaraNot yet recruiting
- Weill Cornell Uptown (Site ID: 7803)New York, United StatesContact: Keisha Ballentine-CargillNot yet recruiting
- New Jersey Medical School Clinical Research Center (Site ID: 31786)Newark, United StatesContact: Christie Lyn CostanzaNot yet recruiting
- University of Pittsburgh (Site ID: 1001)Pittsburgh, United StatesContact: Stacey EdickNot yet recruiting
- UCSD Antiviral Research Center (Site ID: 701)San Diego, United StatesContact: Dawn RosenblumNot yet recruiting
- University of California, San Francisco (Site ID: 801)San Francisco, United StatesContact: Jay DwyerNot yet recruiting
- University of Washington Positive Research (Site ID: 1401)Seattle, United StatesContact: Allysson AngeldekaoNot yet recruiting
- Harbor University of California Los Angeles Center (Site ID: 603)Torrance, United StatesContact: Mario GuerreroNot yet recruiting
- Whitman-Walker Institute, Inc. (Site ID: 21791)Washington D.C., United StatesContact: Avery WimpelbergNot yet recruiting
About the trial
What the trial wants to find out
This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.
The group in the trial
- Long-Acting Lenacapavir Plus Long-Acting CabotegravirTreatment being tested
Treatment: Lenacapavir, Cabotegravir, and Bictegravir/Emtricitabine/Tenofovir Alafenamide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 November 2026